Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.torrentpharma.com | |
Market Cap | 44,656.72 Cr. | |
Enterprise Value(EV) | 48,482.20 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 72.04 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | 36.50 | Trailing Twelve Months Ending 2021-12 |
Industry PE | 28.96 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | 382.23 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | 6.88 | Calculated using Price: 2,629.25 |
Dividend Yield | 1.33 | Period Ending 2021-03 |
No. of Shares Subscribed | 16.92 Cr. | 169,208,720 Shares |
FaceValue | 5 | |
Company Profile | ||
Torrent Pharmaceuticals, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in many countries. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015. In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility. Torrent Pharma is committed towards ‘not just healthcare but lifecare’. Business area of the company Torrent Pharmaceuticals has established itself as a major player in the Indian Pharma arena. The company has well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). With Unichem's domestic business acquisition, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 8 in the IPM. Manufacturing facilities The company’s manufacturing facilities are loaced at Indrad, Dahej, Baddi, Sikkim Unit I & II, Sikkim Unit III, Vizag, Pithampur, Levittown Pennsylvania and HSE Forum. Awards and recognition
Accreditation Approvals research centre
(*Also applicable for Bio-Evaluation Center) Bio-evaluation centre accreditations
Studies inspected and approved
Studies accepted by Regulatory Agencies in:
Milestones
|
1 Day |
|
+0.44% |
1 Week |
|
+2.90% |
1 Month |
|
-7.86% |
3 Month |
|
-1.18% |
6 Month |
|
-5.61% |
1 Year |
|
-3.46% |
2 Year |
|
+5.20% |
5 Year |
|
+100.03% |
10 Year |
|
+730.78% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 33.25 | 39.94 | 34.19 | 57.92 | 23.80 | 15.12 | 9.34 | 21.47 | 23.49 | |
Return on Capital Employed (%) | 31.66 | 35.06 | 26.98 | 45.63 | 20.36 | 13.81 | 9.75 | 15.28 | 17.63 | |
Return on Assets (%) | 12.79 | 15.16 | 11.71 | 20.89 | 10.28 | 5.81 | 3.15 | 7.50 | 9.20 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 1,422 | 1,902 | 2,491 | 3,494 | 4,350 | 4,622 | 4,724 | 4,823 | 5,837 | 6,219 | |
Non Curr. Liab. | 620 | 927 | 2,505 | 1,995 | 2,303 | 4,142 | 3,861 | 3,299 | 2,924 | 2,495 | |
Curr. Liab. | 1,711 | 2,175 | 2,824 | 3,285 | 2,738 | 5,202 | 5,165 | 5,454 | 4,892 | 4,567 | |
Minority Int. | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Equity & Liab. | 3,753 | 5,004 | 7,820 | 8,775 | 9,392 | 13,967 | 13,751 | 13,577 | 13,653 | 13,281 | |
Non Curr. Assets | 1,192 | 1,600 | 3,768 | 4,086 | 4,513 | 8,705 | 8,714 | 8,596 | 8,130 | 7,922 | |
Curr. Assets | 2,561 | 3,404 | 4,051 | 4,689 | 4,879 | 5,262 | 5,038 | 4,981 | 5,523 | 5,359 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 3,753 | 5,004 | 7,820 | 8,775 | 9,392 | 13,967 | 13,751 | 13,577 | 13,653 | 13,281 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 3,211 | 4,185 | 4,653 | 6,667 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,316 | |
Other Income | 43 | 38 | 286 | 229 | 223 | 307 | 64 | 121 | 76 | 178 | |
Total Income | 3,255 | 4,223 | 4,939 | 6,896 | 6,039 | 6,257 | 7,736 | 8,061 | 8,081 | 8,494 | |
Total Expenditure | -2,519 | -3,233 | -3,633 | -3,937 | -4,438 | -4,609 | -5,696 | -5,769 | -5,538 | -5,859 | |
PBIDT | 736 | 990 | 1,306 | 2,959 | 1,601 | 1,648 | 2,040 | 2,292 | 2,542 | 2,635 | |
Interest | -34 | -59 | -175 | -184 | -206 | -308 | -504 | -451 | -358 | -274 | |
Depreciation | -83 | -87 | -191 | -238 | -307 | -409 | -618 | -654 | -658 | -665 | |
Taxation | -147 | -180 | -189 | -610 | -155 | -253 | -125 | -162 | -274 | -477 | |
Exceptional Items | -37 | -194 | -357 | ||||||||
PAT | 435 | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 1,219 | |
Minority Interest | -2 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 433 | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 1,219 | |
Adjusted EPS | 26 | 39 | 44 | 102 | 55 | 40 | 26 | 61 | 74 | 72 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 499 | 153 | 599 | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,011 | |
Cash Fr. Inv. | -137 | -242 | -356 | -2,162 | -838 | -787 | -4,707 | -241 | 199 | -449 | |
Cash Fr. Finan. | -193 | 20 | 86 | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,656 | |
Net Change | 169 | -68 | 330 | -140 | 469 | 29 | -395 | 242 | 42 | -95 | |
Cash & Cash Eqvt | 761 | 687 | 955 | 865 | 1,050 | 1,068 | 702 | 940 | 662 | 573 |
Mon, 16 May 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Issue of Duplicate Share Certificates |
Wed, 11 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 08-Feb-19 kindly find enclosed Annual Secretarial Compliance Report for the year ended on 31-Mar-22 issued by M/s. M. C. Gupta & Co. Practicing Company Secretaries Ahmedabad. |
Wed, 11 May 2022
Board Meeting Outcome for Outcome Of Board Meeting Appointment of Dr. Maurice Chagnaud as an Additional and Independent Director of the Company |
Wed, 18 May 2022 |
|
|
|
|
|